Shandong Pharmaceutical Glass600529.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Shandong Pharmaceutical Glass (600529.SH) trades at a P/E of 17.40x, P/B of 1.41x, P/S of 2.63x, and a dividend yield of 2.55%.
Longitudinal percentile comparison: P/E sits at the 6th percentile over the trailing 10Y window (vs. 19th percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 10th percentile over the trailing 10Y window (vs. 14th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 15th percentile within its industry and the 19th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.55%, ranking at the 95th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 5.4 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shandong Pharmaceutical Glass operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 600529 · SSE: 600529 · 600529
Want the full picture on whether Shandong Pharmaceutical Glass (600529.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 17.40 | ||||||
| P/B (MRQ) | 1.41 | ||||||
| P/S (TTM) | 2.63 | ||||||
| Dividend Yield | 2.55% | ||||||
| Buyback + Div Yield | 2.55% |